

71. Koyama S, Sato E, Nomura H, et al. Monocyte chemotactic factors released from type II pneumocyte-like cells in response to TNF- $\alpha$  and IL-1 $\alpha$ . *Eur Respir J*. 1999;13:820-828.
72. Casola A, Henderson A, Liu T, Garofalo RP, Brasier AR. Regulation of RANTES promoter activation in alveolar epithelial cells after cytokine stimulation. *Am J Physiol Lung Cell Mol Physiol*. 2002;283:L1280-L1290.
73. Rosseau S, Selhorst J, Wiechmann K, et al. Monocyte migration through the alveolar epithelial barrier: adhesion molecule mechanisms and impact of chemokines. *J Immunol*. 2000;164:427-435.
74. Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. *Blood*. 2003;101:2440-2445.
75. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. *J Allergy Clin Immunol*. 2003;111:1185-1199.
76. Serody JS, Burkett SE, Panoskaltis-Mortari A, et al. T-lymphocyte production of macrophage inflammatory protein-1 $\alpha$  is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. *Blood*. 2000;96:2973-2980.
77. Panoskaltis-Mortari A, Hermanson JR, Taras E, Wangenstein OD, Serody JS, Blazar BR. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1 $\alpha$  (CCL3) after allogeneic BMT in mice. *Blood*. 2003;101:3714-3721.
78. Belperio JA, Keane MP, Burdick MD, et al. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. *J Immunol*. 2002;169:1037-1049.
79. Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. *J Clin Invest*. 2001;108:547-556.
80. Piali L, Weber C, LaRosa G, et al. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. *Eur J Immunol*. 1998;28:961-972.
81. Cooke K, Kobzik L, Teshima T, Lowler K, Clouthier S, Ferrara J. A role for Fas-Fas ligand but not perforin mediated cytotoxicity in the development of experimental idiopathic pneumonia syndrome [abstract]. *Blood*. 2000;96:768.

## Erratum

In the article by Roberts et al entitled "The use of recombinant factor VIIa in the treatment of bleeding disorders," which appeared in the December 15, 2004, issue of *Blood* (Volume 104:3858-3864), the following disclosure was inadvertently omitted by the journal: H.R.R. has been a consultant for and has received an honorarium from Novo Nordisk, the manufacturer of recombinant factor VIIa. He is also a consultant to Baxter Bioscience, which manufactures a competing product, and he has received honoraria from Bayer. G.C.W. is a consultant for and has received honoraria from Baxter Bioscience, Bayer, and Novo Nordisk.